The project will explore genetics in Alzheimer’s disease and dementia.
Davos Alzheimer’s Collaborative, global initiative to prevent Alzheimer’s disease and improve brain health, has partnered with biotechnology company PacBio to enhance its research.
The project also brings together The Institute of Global Health and Human Ecology (I-GHHE) at The American University in Cairo (AUC) and UCL Queen Square Institute of Neurology, University College London (UCL).
“We are proud to partner with DAC, AUC, and UCL on this important project to advance our understanding of the genetics of Alzheimer’s disease, and hopefully help researchers identify new diagnostic tools and therapeutic solutions,” said PacBio vice president and general manager of EMEA Neil Ward.
“Our long-read sequencing technology is uniquely suited to deliver the high-quality genomic data needed to explore the complex genetic landscape of Alzheimer’s disease.”
PacBio, a specialist in long-read sequencing platforms, will support Davos’ North African Dementia Registry (NADR) project, using its advanced sequencing technology to generate insights to guide future research, prevention and treatment efforts.
The aim is to develop a comprehensive multi-omics dataset to advance understanding of the genetics in Alzheimer’s disease and dementias in diverse global populations.
With the dataset, researchers can explore new insights into the genetic and environmental factors contributing to Alzheimer’s disease and dementias.
The project will also help to enable biosamples collection, cognitive assessments and digital phenotyping.
“This collaboration will bolster our understanding of Alzheimer’s disease in a region characterized by remarkable genetic diversity,” said Davos executive vice president Vaibhav Narayan.
“Over time, these insights will inform locally relevant prevention and intervention strategies for communities often overlooked in global research efforts.”
